New Recruiting Trial: Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

WHY IT MATTERS

This trial is now actively recruiting patients with newly-diagnosed Ph+ ALL/lymphoma and offers access to ponatinib, a third-generation tyrosine kinase inhibitor that may improve outcomes for this aggressive blood cancer.

Researchers are looking for patients with a specific type of blood cancer called Philadelphia chromosome positive acute lymphoblastic leukemia to test a new treatment combination. The treatment uses chemotherapy drugs (EPOCH), sometimes combined with rituximab (a protein therapy), plus a targeted drug called ponatinib. This is a Phase 2 trial, meaning it's testing whether the treatment works and is safe in a larger group of patients.

NCT ID: NCT07224100 Title: Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Status: RECRUITING Phase: PHASE2 Sponsor: University of Washington Start date: 2026-04-15 URL: https://clinicaltrials.gov/study/NCT07224100 Source: UniteRare clinical trials database

YOU CAN ACT ON THIS

If you or a loved one has been newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoma, contact the University of Washington study team at NCT07224100 on clinicaltrials.gov to learn if you qualify and enroll before the trial reaches capacity.